The stock of ValiRx Plc (LON:VAL) is a huge mover today! The stock increased 5.51% or GBX 0.37 on November 3, hitting GBX 7.12. About 1.17 million shares traded hands. ValiRx Plc (LON:VAL) has declined 25.00% since April 6, 2016 and is downtrending. It has underperformed by 26.21% the S&P500.
The move comes after 6 months positive chart setup for the GBX 5.79M company. It was reported on Nov, 3 by Barchart.com. We have GBX 15.24 PT which if reached, will make LON:VAL worth GBX 6.60 million more.
ValiRx Plc (LON:VAL) Ratings Coverage
Out of 2 analysts covering ValiRx PLC (LON:VAL), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. ValiRx PLC has been the topic of 23 analyst reports since September 16, 2015 according to StockzIntelligence Inc. Beaufort Securities maintained ValiRx Plc (LON:VAL) on Wednesday, September 28 with “Speculative Buy” rating. Northland Capital maintained the shares of VAL in a report on Tuesday, June 7 with “Corporate” rating. The firm has “Corporate” rating given on Thursday, October 1 by Northland Capital. The stock of ValiRx Plc (LON:VAL) has “Corporate” rating given on Thursday, July 14 by Northland Capital. The firm earned “Corporate” rating on Thursday, May 19 by Northland Capital. The stock of ValiRx Plc (LON:VAL) earned “Corporate” rating by Northland Capital on Thursday, November 3. The firm earned “Speculative Buy” rating on Wednesday, September 14 by Beaufort Securities. The firm earned “Corporate” rating on Tuesday, September 13 by Northland Capital. The rating was maintained by Northland Capital with “Corporate” on Friday, April 29. Beaufort Securities maintained the stock with “Speculative Buy” rating in Friday, July 8 report.
Another recent and important ValiRx Plc (LON:VAL) news was published by Uk.Finance.Yahoo.com which published an article titled: “-LSE Ticker: WWYSP4/ISIN: GB00BWWYSP41” on March 17, 2014.
ValiRx plc is a biopharmaceutical company. The company has a market cap of 5.79 million GBP. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It currently has negative earnings. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.